Please assess the completion status of the following clinical trial:

Trial Title: Response to Phenylketonuria to Tetrahydrobiopterin (BH4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject and/or parent or guardian must be capable of understanding and providing written informed consent~* Subjects must have Phenylketonuria (PKU)or hyperphenylalaninemia (HPA), defined as baseline blood Phe levels of \>600 umol/L~* Subjects must be at least 10 years of age, and may be of either gender and any ethnic group~* Female subjects of childbearing potential must agree to use adequate birth control or refrain from sexual activity throughout study participation~Exclusion Criteria:~* Female subjects who are pregnant or breastfeeding~* Subjects who have concurrent diseases or conditions that require medication or treatment~* Subjects who require concomitant treatment with any drug known to inhibit folate synthesis~* Subjects who have been treated with any investigational drug within 30 days

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
- Control Arm (Type: PLACEBO_COMPARATOR): Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.

Based on this trial design, predict the completion outcome and termination type (if applicable).